BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis C

NCT01389323 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

448

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: Daclatasvir
DRUG: Peg-Interferon Alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb